These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16652143)

  • 21. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
    Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
    Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.
    Zhou J; Chen X; Gilvary DL; Tejera MM; Eksioglu EA; Wei S; Djeu JY
    Sci Rep; 2015 Oct; 5():15085. PubMed ID: 26469759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.
    Fulda S; Debatin KM
    Oncogene; 2002 Apr; 21(15):2295-308. PubMed ID: 11948413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
    Gan L; Wang J; Xu H; Yang X
    Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signal transducer and activator of transcription 1 (Stat1) maintains basal mRNA expression of pro-survival stat3-target genes in glioma C6 cells.
    Adach-Kilon A; Swiatek-Machado K; Kaminska B; Dabrowski M
    J Cell Biochem; 2011 Dec; 112(12):3685-94. PubMed ID: 21815198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
    Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullén A; Yachnin J; Nilsson S; Panaretakis T
    Oncotarget; 2015 Aug; 6(25):21740-54. PubMed ID: 25844599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy-induced tumor gene expression changes in human breast cancers.
    Lee SC; Xu X; Lim YW; Iau P; Sukri N; Lim SE; Yap HL; Yeo WL; Tan P; Tan SH; McLeod H; Goh BC
    Pharmacogenet Genomics; 2009 Mar; 19(3):181-92. PubMed ID: 19352302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
    Wen X; Li X; Liao B; Liu Y; Wu J; Yuan X; Ouyang B; Sun Q; Gao X
    Urology; 2009 Jun; 73(6):1407-11. PubMed ID: 19362342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
    Zhang Y; Wang Y; Yuan J; Qin W; Liu F; Wang F; Zhang G; Yang X
    Cell Biol Toxicol; 2012 Aug; 28(4):269-77. PubMed ID: 22648782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
    Hara T; Ushio K; Nishiwaki M; Kouno J; Araki H; Hikichi Y; Hattori M; Imai Y; Yamaoka M
    Cell Biol Int; 2010 Jan; 34(2):177-84. PubMed ID: 19947927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thapsigargin resistance in human prostate cancer cells.
    O'Neill JP; Velalar CN; Lee DI; Zhang B; Nakanishi T; Tang Y; Selaru F; Ross D; Meltzer SJ; Hussain A
    Cancer; 2006 Aug; 107(3):649-59. PubMed ID: 16770788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
    Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
    Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
    Corcoran C; Rani S; O'Brien K; O'Neill A; Prencipe M; Sheikh R; Webb G; McDermott R; Watson W; Crown J; O'Driscoll L
    PLoS One; 2012; 7(12):e50999. PubMed ID: 23251413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
    Kosaka T; Miyajima A; Shirotake S; Suzuki E; Kikuchi E; Oya M
    J Urol; 2011 Jun; 185(6):2376-81. PubMed ID: 21511293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.